University of California

The University of Queensland

Dendrocyte Biotech Pty Ltd

Kira Biotech Pty Limited

Transbio Ltd

Derek Nigel John Hart

James David Marks

David John Munster

Trent Phillip Munro

Therese Ann Seldon

Martina Louise Jones

Stephen Michael Mahler

Yu Zhou

Eunice Yu Zhou

Georgina Jane Clark

Robin Gasiorowski

The present disclosure relates to an isolated antibody, or antigen binding fragment thereof, which specifically binds to an extracellular domain of cd300f, wherein the antibody, or antigen binding fragment thereof, comprises a heavy chain variable region which comprises: (a) an amino acid sequence that is at least 70% identical to the amino acid sequence represented by seq id no: 1; and/or (b) a complementarity determining region 1 (cdr1) that comprises the amino acid sequence represented by seq id no: 2, a complementarity determining region 2 (cdr2) that comprises an amino acid sequence that is represented by seq id no: 3, and/or a complementarity determining region 3 (cdr3) that comprises an amino acid sequence that is represented by seq id no: 4, compositions comprising the antibody, antigen binding fragment thereof, and uses for therapy.

Anti-CD300F antibody and uses thereof

The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis, or prognosis.

Anti-CD83 antibodies and use thereof

The present disclosure relates to proteins that bind to CD83 and uses thereof, for example, in therapy, prophylaxis, diagnosis or prognosis.

Growing community of inventors

Concord, Australia

Derek Nigel John Hart